HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Triplitt, C. Articles by DeFronzo, R. A. Search for Related Content PubMed PubMed Citation Articles by Triplitt, C. Articles by DeFronzo, R. A. Social Bookmarking                What's this?

Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea

From the Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio and the Texas Diabetes Institute, San Antonio, Texas

Address correspondence and reprint requests to Ralph A. DeFronzo, MD, Diabetes Division, MSC 7886, University of Texas Health Science Center, San Antonio, TX 78229-3900. E-mail: albarado{at}uthscsa.edu

OBJECTIVE—We sought to examine the mechanisms by which the addition of glargine insulin or rosiglitazone improves glycemic control in type 2 diabetic subjects poorly controlled on maximally effective doses of metformin plus sulfonylurea.

RESEARCH DESIGN AND METHODS—Subjects (aged 47 ± 11 years, BMI 31 ± 5 kg/m², HbA_1c [A1C] 9.4 ± 1.3%) received bedtime glargine insulin (titrated based on the fasting plasma glucose [FPG], n = 10) or rosiglitazone (4 mg twice daily, n = 10). At baseline and after 4 months, A1C was measured and an oral glucose tolerance test and a 3-h euglycemic insulin (80 mU/m² per min) clamp with [3-³H]glucose were performed.

RESULTS—A1C and FPG decreased similarly in the glargine insulin (9.1 ± 0.4 to 7.6 ± 0.3% and 212 ± 14 to 139 ± 5 mg/dl, respectively, both P < 0.0001) and rosiglitazone (9.4 ± 0.3 to 7.6 ± 0.4% and 223 ± 14 to 160 ± 19 mg/dl, respectively, both P < 0.005) groups. After 4 months, endogenous glucose production (EGP) declined similarly with glargine insulin (2.27 ± 0.10 to 1.73 ± 0.12 mg · kg^–1 · min^–1, P < 0.0001) and rosiglitazone (2.21 ± 0.12 to 1.88 ± 0.12 mg · kg^–1 · min^–1, P = 0.01). The hepatic insulin resistance index declined in the rosiglitazone group (32 ± 3 to 21 ± 1 mg · kg^–1 · min^–1 x µU/ml, P = 0.03 vs. baseline and P < 0.05 vs. glargine insulin) and did not change in the glargine group (22 ± 5 to 20 ± 3 mg · kg^–1 · min^–1 x µU/ml, P = NS). At 4 months, glargine insulin (3.6 ± 0.5 to 4.2 ± 0.4 mg · kg^–1 · min^–1, P < 0.01) and rosiglitazone (2.7 ± 0.3 to 3.8 ± 0.3 mg · kg^–1 · min^–1, P < 0.0005) increased R_d, but the increment was greater in the rosiglitazone group (P < 0.05). Diastolic blood pressure was reduced only by rosiglitazone (P < 0.01).

CONCLUSIONS—Triple therapy with glargine insulin or rosiglitazone similarly reduced A1C, primarily by suppressing basal EGP (hepatic). Glargine insulin reduced basal EGP by increasing plasma insulin levels, while rosiglitazone decreased basal hepatic glucose production by improving hepatic insulin sensitivity.

Abbreviations: CRC, clinical research center • EGP, endogenous glucose production • FFA, free fatty acid • FPG, fasting plasma glucose • FPI, fasting plasma insulin • IRI, insulin resistance index • OGTT, oral glucose tolerance test • TGD, total glucose disposal

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?